Nirsevimab Prophylaxis and Respiratory Syncytial Virus Hospitalizations Among Infants

Is nirsevimab prophylaxis associated with respiratory syncytial virus (RSV)–related hospitalization risk among infants, particularly in high-risk groups?In this cohort study of 13 624 infants in Italy, nirsevimab population coverage of 79% was associated with a significantly lower population-level and individual-level hazard of RSV hospitalization.These findings suggest that nirsevimab prophylaxis is associated with substantially lower RSV hospitalization risk, but targeted supplemental strategies may be needed for high-risk infants to further reduce RSV burden.

Corresponding Author: Enrico Cocchi, MD, PhD, Department of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum–University of Bologna, Via G. Massarenti 9, 40138 Bologna, Emilia-Romagna, Italy (enrico.cocchi3@unibo.it).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.